Examkin

Soru

Zorluk: OrtaClinical Preventive Services and Screening

A 45-year-old man comes to the clinic to establish care. He has not seen a physician in over a decade and feels entirely well. He has no history of injection drug use, tattoos, or blood transfusions. Physical examination is unremarkable. According to current United States Preventive Services Task Force (USPSTF) guidelines, universal screening for Hepatitis C is indicated. Assuming all diagnostic findings are positive, arrange the following steps in the most appropriate chronological sequence for the screening, confirmation, and management of Hepatitis C in this patient.

  1. 1Hepatitis C virus (HCV) antibody testing
  2. 2Quantitative HCV RNA polymerase chain reaction (PCR)
  3. 3Assessment of hepatic fibrosis (e.g., transient elastography)
  4. 4Initiation of direct-acting antiviral (DAA) therapy

Cevap

The correct chronological sequence is: 1) Hepatitis C virus (HCV) antibody testing, 2) Quantitative HCV RNA polymerase chain reaction (PCR), 3) Assessment of hepatic fibrosis (e.g., transient elastography), 4) Initiation of direct-acting antiviral (DAA) therapy.
According to USPSTF guidelines, all adults aged 18 to 79 years should receive a one-time screening for Hepatitis C using an HCV antibody test. If this screening is positive, it must be followed by a quantitative HCV RNA PCR to confirm active infection, as antibodies remain positive even in patients who have spontaneously cleared the virus. Once chronic HCV infection is confirmed by a positive RNA test, the patient must undergo an assessment of hepatic fibrosis (e.g., using non-invasive methods like transient elastography or biomarker panels). Fibrosis staging is a critical prerequisite to initiating direct-acting antiviral (DAA) therapy, as the presence of cirrhosis alters the choice of DAA regimen, extends the required treatment duration, and mandates ongoing surveillance for hepatocellular carcinoma and esophageal varices. Finally, appropriate DAA therapy is initiated to eradicate the virus.

Adım Adım Çözüm

1
Determine the appropriate initial screening test for a 45-year-old asymptomatic patient.
Hepatitis C virus (HCV) antibody testing is selected.
The USPSTF recommends one-time universal screening for HCV in all adults aged 18 to 79 years using an HCV antibody test.
2
Identify the next step for a positive HCV antibody result.
Quantitative HCV RNA PCR is selected.
A positive HCV antibody test indicates exposure but cannot differentiate between active infection and spontaneous clearance. HCV RNA testing confirms active viremia.
3
Determine the required evaluation before initiating treatment for confirmed active HCV.
Assessment of hepatic fibrosis is selected.
Before starting direct-acting antivirals, staging liver fibrosis is required to tailor the treatment regimen and duration, and to determine if the patient has cirrhosis requiring hepatocellular carcinoma surveillance.
4
Identify the final definitive management step.
Initiation of direct-acting antiviral (DAA) therapy is selected.
Once active infection is confirmed and liver disease is staged, DAAs are prescribed to achieve a sustained virologic response.

Anahtar Kavram

Hepatitis C Universal Screening and Management Cascade
Bu soruyu puanla

Konular

Clinical Preventive Services and Screening

Bu konudan daha fazla soru